Jose-Alberto Palma1, Jose Martinez1, Patricio Millar Vernetti1, Thong Ma1, Miguel A Perez1, Judy Zhong2, Yingzhi Qian2, Suman Dutta3, Katherine N Maina3, Ibrar Siddique3, Gal Bitan3,4,5, Benjamin Ades-Aron6, Timothy M Shepherd6, Un J Kang1, Horacio Kaufmann1. 1. Department of Neurology, New York University Grossman School of Medicine, New York, New York, USA. 2. Department of Population Health, Division of Biostatistics, New York University Grossman School of Medicine, New York, New York, USA. 3. Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA. 4. Brain Research Institute, University of California, Los Angeles, California, USA. 5. Molecular Biology Institute, University of California, Los Angeles, California, USA. 6. Department of Radiology, New York University Grossman School of Medicine, New York, New York, USA.
Abstract
BACKGROUND: Multiple system atrophy (MSA) is a fatal neurodegenerative disease characterized by the aggregation of α-synuclein in glia and neurons. Sirolimus (rapamycin) is an mTOR inhibitor that promotes α-synuclein autophagy and reduces its associated neurotoxicity in preclinical models. OBJECTIVE: To investigate the efficacy and safety of sirolimus in patients with MSA using a futility design. We also analyzed 1-year biomarker trajectories in the trial participants. METHODS: Randomized, double-blind, parallel group, placebo-controlled clinical trial at the New York University of patients with probable MSA randomly assigned (3:1) to sirolimus (2-6 mg daily) for 48 weeks or placebo. Primary endpoint was change in the Unified MSA Rating Scale (UMSARS) total score from baseline to 48 weeks. (ClinicalTrials.gov NCT03589976). RESULTS: The trial was stopped after a pre-planned interim analysis met futility criteria. Between August 15, 2018 and November 15, 2020, 54 participants were screened, and 47 enrolled and randomly assigned (35 sirolimus, 12 placebo). Of those randomized, 34 were included in the intention-to-treat analysis. There was no difference in change from baseline to week 48 between the sirolimus and placebo in UMSARS total score (mean difference, 2.66; 95% CI, -7.35-6.91; P = 0.648). There was no difference in UMSARS-1 and UMSARS-2 scores either. UMSARS scores changes were similar to those reported in natural history studies. Neuroimaging and blood biomarker results were similar in the sirolimus and placebo groups. Adverse events were more frequent with sirolimus. Analysis of 1-year biomarker trajectories in all participants showed that increases in blood neurofilament light chain (NfL) and reductions in whole brain volume correlated best with UMSARS progression. CONCLUSIONS: Sirolimus for 48 weeks was futile to slow the progression of MSA and had no effect on biomarkers compared to placebo. One-year change in blood NfL and whole brain atrophy are promising biomarkers of disease progression for future clinical trials.
BACKGROUND: Multiple system atrophy (MSA) is a fatal neurodegenerative disease characterized by the aggregation of α-synuclein in glia and neurons. Sirolimus (rapamycin) is an mTOR inhibitor that promotes α-synuclein autophagy and reduces its associated neurotoxicity in preclinical models. OBJECTIVE: To investigate the efficacy and safety of sirolimus in patients with MSA using a futility design. We also analyzed 1-year biomarker trajectories in the trial participants. METHODS: Randomized, double-blind, parallel group, placebo-controlled clinical trial at the New York University of patients with probable MSA randomly assigned (3:1) to sirolimus (2-6 mg daily) for 48 weeks or placebo. Primary endpoint was change in the Unified MSA Rating Scale (UMSARS) total score from baseline to 48 weeks. (ClinicalTrials.gov NCT03589976). RESULTS: The trial was stopped after a pre-planned interim analysis met futility criteria. Between August 15, 2018 and November 15, 2020, 54 participants were screened, and 47 enrolled and randomly assigned (35 sirolimus, 12 placebo). Of those randomized, 34 were included in the intention-to-treat analysis. There was no difference in change from baseline to week 48 between the sirolimus and placebo in UMSARS total score (mean difference, 2.66; 95% CI, -7.35-6.91; P = 0.648). There was no difference in UMSARS-1 and UMSARS-2 scores either. UMSARS scores changes were similar to those reported in natural history studies. Neuroimaging and blood biomarker results were similar in the sirolimus and placebo groups. Adverse events were more frequent with sirolimus. Analysis of 1-year biomarker trajectories in all participants showed that increases in blood neurofilament light chain (NfL) and reductions in whole brain volume correlated best with UMSARS progression. CONCLUSIONS: Sirolimus for 48 weeks was futile to slow the progression of MSA and had no effect on biomarkers compared to placebo. One-year change in blood NfL and whole brain atrophy are promising biomarkers of disease progression for future clinical trials.
Authors: Johannes Levin; Sylvia Maaß; Madeleine Schuberth; Armin Giese; Wolfgang H Oertel; Werner Poewe; Claudia Trenkwalder; Gregor K Wenning; Ulrich Mansmann; Martin Südmeyer; Karla Eggert; Brit Mollenhauer; Axel Lipp; Matthias Löhle; Joseph Classen; Alexander Münchau; Jan Kassubek; Florin Gandor; Daniela Berg; Silvia Egert-Schwender; Cornelia Eberhardt; Friedemann Paul; Kai Bötzel; Birgit Ertl-Wagner; Hans-Jürgen Huppertz; Ingrid Ricard; Günter U Höglinger Journal: Lancet Neurol Date: 2019-07-02 Impact factor: 44.182
Authors: Antonella Caccamo; Andrea Magrì; David X Medina; Elena V Wisely; Manuel F López-Aranda; Alcino J Silva; Salvatore Oddo Journal: Aging Cell Date: 2013-03-24 Impact factor: 9.304
Authors: Mickael Decressac; Bengt Mattsson; Pia Weikop; Martin Lundblad; Johan Jakobsson; Anders Björklund Journal: Proc Natl Acad Sci U S A Date: 2013-04-22 Impact factor: 11.205
Authors: S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet Journal: Neurology Date: 2008-08-26 Impact factor: 9.910
Authors: Jose-Alberto Palma; Patricio Millar Vernetti; Miguel A Perez; Florian Krismer; Klaus Seppi; Alessandra Fanciulli; Wolfgang Singer; Phillip Low; Italo Biaggioni; Lucy Norcliffe-Kaufmann; Maria Teresa Pellecchia; Maria José Martí; Han-Joon Kim; Marcelo Merello; Iva Stankovic; Werner Poewe; Rebecca Betensky; Gregor Wenning; Horacio Kaufmann Journal: Clin Auton Res Date: 2021-02-07 Impact factor: 4.435
Authors: Gregor K Wenning; Felix Geser; Florian Krismer; Klaus Seppi; Susanne Duerr; Sylvia Boesch; Martin Köllensperger; Georg Goebel; Karl P Pfeiffer; Paolo Barone; Maria Teresa Pellecchia; Niall P Quinn; Vasiliki Koukouni; Clare J Fowler; Anette Schrag; Christopher J Mathias; Nir Giladi; Tanya Gurevich; Erik Dupont; Karen Ostergaard; Christer F Nilsson; Håkan Widner; Wolfgang Oertel; Karla Maria Eggert; Alberto Albanese; Francesca del Sorbo; Eduardo Tolosa; Adriana Cardozo; Günther Deuschl; Helge Hellriegel; Thomas Klockgether; Richard Dodel; Cristina Sampaio; Miguel Coelho; Ruth Djaldetti; Eldad Melamed; Thomas Gasser; Christoph Kamm; Giuseppe Meco; Carlo Colosimo; Olivier Rascol; Wassilios G Meissner; François Tison; Werner Poewe Journal: Lancet Neurol Date: 2013-02-05 Impact factor: 44.182
Authors: Tim F Cloughesy; Koji Yoshimoto; Phioanh Nghiemphu; Kevin Brown; Julie Dang; Shaojun Zhu; Teli Hsueh; Yinan Chen; Wei Wang; David Youngkin; Linda Liau; Neil Martin; Don Becker; Marvin Bergsneider; Albert Lai; Richard Green; Tom Oglesby; Michael Koleto; Jeff Trent; Steve Horvath; Paul S Mischel; Ingo K Mellinghoff; Charles L Sawyers Journal: PLoS Med Date: 2008-01-22 Impact factor: 11.069